KY has received honoraria or lecture fees from AbbVie, Amgen Inc., AstraZeneca plc, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo, Janssen Pharmaceuticals, Kyowa Kirin Co., Ltd, Lilly, Merck Serono, Novartis, Ono Pharmaceutical Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Taiho Pharmaceutical Co., Ltd, and Takeda Pharmaceutical Co., Ltd; has received grants from AbbVie, Amgen Inc., AstraZeneca plc, Boehringer Ingelheim, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo, Eli Lilly, MSD, Pfizer, Taiho Pharmaceutical Co., Ltd, and Takeda Pharmaceutical Co., Ltd. KA has received honoraria from AstraZeneca plc, Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd, MSD, Nippon Kayaku Co., Ltd, and Ono Pharmaceutical Co., Ltd. HH has received honoraria from Amgen Inc., AstraZeneca K.K, Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd, Daiichi-Sankyo K.K., Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd, and Pfizer Japan Inc; has received fees for promotional materials from Guardant Health Japan Corp.; has received research funding from A2 Healthcare Corporation, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca K.K., Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd, CMIC Holdings Co., Ltd, Covance Japan Inc., Daiichi Sankyo Co., Ltd, Eisai Co., Ltd, EPS Corporation, GlaxoSmithKline K.K., IQVIA Services Japan K.K., Japan Clinical Research Operations, Janssen Pharmaceutical K.K., MSD K.K., Nippon Boehringer Ingelheim Co., Ltd, Novartis Pharma K.K., Pfizer R&D Japan G.K., PRA Health Sciences Inc., Sanofi K.K., Syneos Health clinical K.K., Taiho Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, and West Japan Oncology Group; has received scholarship donations from Chugai Pharmaceutical Co., Ltd, Eisai Co., Ltd, Ono Pharmaceutical Co., Ltd, and Takeda Pharmaceutical Co., Ltd. MN has received honoraria or lecture fees from AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo, Eli Lilly, Janssen, MSD, Nippon Kayaku, Novartis, Ono Pharmaceutical Co., Ltd, Pfizer, Taiho Pharmaceutical Co. Ltd, and Takeda Pharmaceutical Co., Ltd. KC has received honoraria from AstraZeneca, Chugai Co., Ltd, Eli Lilly, MSD, and Taiho Pharmaceutical Co., Ltd. EI has received honoraria from Eli Lilly; has received research funding from Janssen Pharmaceuticals, MSD, Ono Pharmaceutical Co., Ltd, and Takeda Pharmaceutical Co., Ltd. YW reports no conflicts of interest. TA and TK are employees and stock owners of Takeda Pharmaceutical Co., Ltd. RF is an employee and stock owner of Takeda Development Center Americas, Inc. YO has received honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo, Eisai Co. Ltd, Eli Lilly, Kyowa Hakko Kirin Co., Ltd, MSD, Nippon Kayaku, Ono Pharmaceutical Co., Ltd, Pfizer, and Taiho Pharmaceutical Co., Ltd; has received research funding from AstraZeneca, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo, Eli Lilly, Janssen, Kissei Pharmaceutical, Kyowa Hakko Kirrin Co., Ltd, LOXO Oncology, Novartis, Pfizer, Sumitomo Pharma Co., Ltd, Taiho Pharmaceutical Co., Ltd, and Takeda Pharmaceutical Co., Ltd.